Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06668935 · ClinicalTrials.gov registry record

Prolongation of GLP-1 Adherence When Using Continuous Glucose Monitoring

A clinical trial of Diabetes Mellitus, sponsored by Abbott Diabetes Care.

Recruiting
Registry status
800
Enrollment target
2
Study locations

NCT06668935: Recruiting study of Diabetes Mellitus, sponsored by Abbott Diabetes Care.

NCT06668935 is a study of Diabetes Mellitus that is actively recruiting participants, run by Abbott Diabetes Care. The registered enrollment target is 800 participants, below the 1,864-participant average among 208 other Diabetes Mellitus trials with a reported enrollment target (57% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06668935, a study of Diabetes Mellitus, is actively recruiting participants, sponsored by Abbott Diabetes Care.

RECRUITING
Registry status
800 participants
Enrollment target
2
Study locations

Study Summary

This study is to see if the FreeStyle Libre 3 Continuous Glucose Monitoring System (FSL3) will help prolong the length of time people with diabetes maintain adherence to glucagon-like peptide 1 (GLP-1/GIP) agonists.

Primary Outcome

The primary outcome is to see if the FreeStyle Libre 3 Continuous Glucose Monitoring System (FSL3) helps prolong the length of time people with diabetes maintain adherence to glucagon-like peptide 1 (GLP-1) and dual gastric inhibitory polypeptide/glucagon-like peptide 1 (GIP/GLP-1) agonists.

Conditions Studied

Interventions

  • DEVICE To utilize the FreeStyle Libre 3 Continuous Glucose Monitoring System (FSL3) to help prolong the length of time people with diabetes maintain adherence to GLP-1 and dual GIP/GLP-1 agonists

Study Locations (2)

Florida

  • East Coast Institute for Research, LLC - Jacksonville
  • Excellence Medical and Research - Miami Gardens

Trial Details

FieldValue
Enrollment Target 800 participants
Start Date 2024-10-24
Est. Completion 2027-01
Abbott Diabetes Care

26 total trials

What NCT06668935 shows while recruiting

NCT06668935 is an observational study that tracks outcomes without assigning an intervention. The registered 800 participants enrollment target is mid-sized for trials with a published cap, below the 1,864-participant average among 208 other Diabetes Mellitus trials with a reported enrollment target (57% lower).

The record links to 1 condition, with Diabetes Mellitus appearing as the primary indexed condition, and to 1 intervention - of which To utilize the FreeStyle Libre 3 Continuous Glucose Monitoring System (FSL3) to help prolong the length of time people with diabetes maintain adherence to GLP-1 and dual GIP/GLP-1 agonists is the first listed.

NCT06668935 reports a single indexed study location in Florida.

Frequently Asked Questions

What is clinical trial NCT06668935 about?

NCT06668935 is a clinical study titled "Prolongation of GLP-1 Adherence When Using Continuous Glucose Monitoring". This study is to see if the FreeStyle Libre 3 Continuous Glucose Monitoring System (FSL3) will help prolong the length of time people with diabetes maintain adherence to glucagon-like peptide 1 (GLP-1/GIP) agonists.

What is the current status of trial NCT06668935?

This trial is currently recruiting. The enrollment target is 800 participants. The study started on 2024-10-24. Estimated completion is 2027-01.

What conditions does trial NCT06668935 study?

This clinical trial studies the following conditions: Diabetes Mellitus.

What interventions are being tested in trial NCT06668935?

The interventions under investigation include: To utilize the FreeStyle Libre 3 Continuous Glucose Monitoring System (FSL3) to help prolong the length of time people with diabetes maintain adherence to GLP-1 and dual GIP/GLP-1 agonists (DEVICE).

Who is sponsoring clinical trial NCT06668935?

This trial is sponsored by Abbott Diabetes Care, which has 26 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06668935 being conducted?

This trial has 2 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Diabetes Mellitus

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06668935's enrollment target sits among peer trials

800 30th of 208 higher than 179 of 208 other Diabetes Mellitus trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Diabetes Mellitus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00695214 · 800 participants · Phase 2

    Drug-Induced Sleep Endoscopy for Upper Airway Evaluation in Obstructive Sleep Apnea

  • NCT03048201 · 800 participants · NA

    Physica System Total Knee Replacement Registry Study

  • NCT03792659 · 800 participants

    The EXPLORE MG Registry for Myasthenia Gravis

  • NCT03819296 · 800 participants · Phase 1

    Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06668935, the US trial registry maintained by the National Library of Medicine. NCT06668935 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.